Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Edderd who wrote (9433)	6/9/1998 6:46:00 PM
From: Mkilloran	Read Replies (1) \| Respond to of 23519

Edderd....They signed an agreement with Jansen with royalty agreement it was reported in the 10k....not a lot of details... But I do believe it is better than a one time milestone fee.... Remember Vivus was the only game in town last year when Astra and Jansen were fighting for distribution rights ..... Also the fact that Japan is not spoken for yet....I think Vivus was holding back on that till later....The market in Japan for a product like this will be big....price will not be an issue.... Vivus needs to get the scripts up over the next couple of months so the analyst and distributors can project cleared market size for Muse and next generation product "ALIBRA" worldwide... The time to cut a deal for Japan is in the 4th qtr this year....IMO